查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1869685

抗高血压药物市场规模、份额和趋势分析报告：按产品、类型、给药途径、分销管道、地区和细分市场预测（2025-2033 年）

Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report By Product, By Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

抗高血压药物市场摘要

2024年全球抗高血压药物市场规模估计为248.8亿美元，预计2033年将达到353.2亿美元。

预计从 2025 年到 2033 年，该市场将以 3.96% 的复合年增长率成长。推动该市场成长的因素包括人口老化、久坐的生活方式、肥胖以及都市化导致的高血压病例增加。

推动市场需求成长的因素包括：人们对心血管疾病的认识不断提高、药物研发的进步、新型固定剂量组合药物的推出以及诊断技术的改进。新兴国家医疗基础设施的扩张也进一步促进了市场扩张。

高血压会增加心臟病和中风的风险，而心臟病和中风是美国的主要死因。根据美国疾病管制与预防中心 (CDC) 2025 年 1 月发布的数据，高血压影响着近一半的美国成年人，每年导致超过 66.4 万人死亡，并造成 1,310 亿美元的经济损失。男性高血压盛行率 (50%) 高于女性 (44%)，其中黑人成年人盛行率最高 (58%)，其次是白人 (49%)、亚裔 (45%) 和西班牙裔 (39%)。只有四分之一的高血压患者血压得到控制，且不同性别、种族和地区之间存在差异。数百万高血压患者，尤其是重度高血压患者，仍未接受治疗。高血压控制不佳的高盛行率和低治疗依从性导致对降血压药物的需求旺盛。高血压为医疗保健系统带来的不断增长的成本，正在推动对有效治疗方法的进一步投资，并促进全球降血压药物产业的发展。

近期监管部门的核准和积极的临床试验结果正在推动市场成长并重塑治疗策略。例如，2025年6月，乔治医药公司（George Medicines）的维达普瑞（Widapric）获得美国食品药物管理局（FDA）批准，这是全球首个也是目前唯一一个用于治疗成人高血压（包括一线核准）的单片联合治疗（Telmisartan、氨氯地平和吲达帕胺）。维达普瑞提供三种剂量规格，满足了高血压治疗中常见的多种药物联合用药的需求，并以便捷的剂型提供联合治疗的优势。

预计于2025年第四季在美国商业性，并计划提交其他全球监管申请。 WIDAPLIK的核准代表着抗高血压行业的一项重大创新，它为新确诊和血压控制不佳的患者带来了一种便捷的、First-in-Class的三联联合治疗。简化治疗方案并提高用药依从性将有助于满足美国市场的强劲需求，因为美国约有一半的成年人患有高血压，但只有四分之一的患者得到了有效控制。此次核准有望推动单片疗法的普及，并在全球范围内树立高血压管理的新标准。

此外，2024年4月，Alnylam Pharmaceuticals公司宣布了其在研RNAi疗法dilbesiran的II期KARDIA-2试验的正面结果。此疗法针对血管张力素原（AGT），用于治疗难治性高血压。单次皮下注射600毫克dilbesiran，并搭配标准降血压药物（吲达帕胺、氨氯地平或Olmesartan），三个月后患者的收缩压显着降低，降幅高达12.1 mmHg，且疗效可持续至六个月。

迪贝西兰是第一个用于治疗高血压的RNAi疗法药物，它是一种长效药物，每年只需给药两次，有望为传统的口服降血压药市场带来新的选择。透过提高患者的用药依从性并实现持续的血压控制，它满足了未控制高血压患者的巨大未满足医疗需求。该药物的成功有望将精准医疗和生物製药疗法的应用范围扩展到传统治疗方法之外，并彻底改变降血压药产业。

目录

第一章调查方法和范围

第二章执行摘要

第三章 抗高血压药物市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析

第四章 抗高血压药物市场：产品业务分析

  • 产品市场份额，2024 年和 2033 年
  • 产品细分仪表板
  • 市场规模、预测与趋势分析（按产品划分，2021-2033 年）
  • 血管紧张素转换酶抑制剂（ACEI）
  • 血管收缩素II受体阻断剂（ARB）
  • 直接肾素抑制剂
  • 钙离子通道阻断剂
  • 利尿剂
  • 盐皮质激素受体拮抗剂（MRA）
  • β受体阻断剂
  • α1阻断剂
  • 中枢α2促效剂
  • 直接血管扩张剂
  • 固定剂量组合药物（FDCs）
  • 其他的

第五章 抗高血压药物市场：按类型分類的业务分析

  • 按类型分類的市场份额，2024 年和 2033 年
  • 类型细分仪表板
  • 按类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 正常高血压
  • 难治性高血压
  • 高血压急症

第六章：抗高血压药物市场：依给药途径进行业务分析

  • 按给药途径分類的市场份额，2024 年和 2033 年
  • 管理路线细分仪表板
  • 按管理途径分類的市场规模、预测和趋势分析，2021-2033年
  • 口服
  • 经皮
  • 肠外/静脉注射

第七章 抗高血压药物市场：通路的业务分析

  • 2024 年及 2033 年分销通路市场份额
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析，2021-2033年
  • 零售药房
  • 医院药房
  • 其他的

第八章：抗高血压药物市场：国家估算与趋势分析

  • 2024 年及 2033 年各国市场
  • 各国市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Novartis
    • Sanofi
    • Bayer
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz（Novartis）
    • Sun Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-772-2

Anti-hypertensive Drugs Market Summary

The global anti-hypertensive drugs market size was estimated at USD 24.88 billion in 2024 and is projected to reach USD 35.32 billion by 2033, growing at a CAGR of 3.96% from 2025 to 2033. The market is driven by the rising prevalence of hypertension due to aging populations, sedentary lifestyles, obesity, and urbanization.

Increasing awareness of cardiovascular health, advances in drug development, introduction of novel fixed-dose combinations, and improved diagnostics are boosting demand. Expanding healthcare infrastructure in emerging economies further supports market expansion.

High blood pressure (hypertension) increases the risk of heart disease and stroke, two major causes of death in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC) in January 2025, High blood pressure affects nearly half of U.S. adults, causes over 664,000 deaths annually, and costs USD 131 billion each year. Prevalence is higher in men (50%) vs. women (44%), and highest among Black adults (58%), followed by Whites (49%), Asians (45%), and Hispanics (39%). Only 1 in 4 people with hypertension have it under control, with disparities across sex, race, and geography. Millions remain untreated, especially those with severely elevated blood pressure. The high prevalence of uncontrolled hypertension and low treatment adherence has driven strong demand for antihypertensive drugs. Rising costs of hypertension to the healthcare system further support investment in effective therapies, expanding the global anti-hypertensive drugs industry.

Recent regulatory approvals and positive clinical trial outcomes have accelerated market growth and reshaped therapeutic strategies. For instance, in June 2025, George Medicines received FDA approval for WIDAPLIK, the first and only single-pill triple combination therapy (telmisartan, amlodipine, indapamide) for hypertension in adults, including as an initial treatment. Available in three dosage strengths, WIDAPLIK offers the benefits of combination therapy in a simplified form, addressing the common need for multiple medications in hypertension management.

The U.S. commercial launch is expected in Q4 2025, with additional global regulatory submissions planned. The approval of WIDAPLIK marks a significant innovation in the anti-hypertensive drugs industry, introducing a convenient, first-in-class triple combination therapy for newly diagnosed and uncontrolled patients. By simplifying treatment and improving adherence, it is expected to capture strong demand in the US, where nearly half of adults have hypertension but only one in four has it under control. This approval strengthens the shift towards single-pill combinations and is likely to set new benchmarks for hypertension management globally.

Furthermore, in April 2024, Alnylam Pharmaceuticals announced positive results from the Phase 2 KARDIA-2 trial, evaluating zilebesiran, an investigational RNAi-based therapy targeting angiotensinogen (AGT) for uncontrolled hypertension. A single 600 mg subcutaneous dose added to standard antihypertensives (indapamide, amlodipine, or olmesartan) achieved significant reductions in ambulatory systolic BP of up to 12.1 mmHg at 3 months and sustained reductions up to 6 months.

Zilebesiran represents a first-in-class RNAi therapeutic in hypertension, offering a long-acting, twice-yearly dosing option that could disrupt the traditional oral drug market. By improving adherence and providing consistent BP control, it targets a major unmet need in patients with uncontrolled hypertension. Its success could significantly reshape the anti-hypertensive drugs industry, expanding precision and biologics-based approaches beyond conventional therapies.

Global Anti-hypertensive Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global anti-hypertensive drugs market report based on product, type, route of administration, distribution channel, and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • ACE Inhibitors (ACEIs)
  • Angiotensin II Receptor Blockers (ARBs)
  • Direct Renin Inhibitor
  • Calcium Channel Blockers
  • Diuretics
  • Mineralocorticoid Receptor Antagonists (MRAs)
  • Beta-blockers
  • Alpha-1 Blockers
  • Central Alpha-2 Agonists
  • Direct Vasodilators
  • Fixed-dose Combinations (FDCs)
  • Others
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Standard Hypertension
  • Treatment-resistant Hypertension
  • Hypertensive Emergency/ Urgency
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Transdermal
  • Parenteral / Intravenous
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail Pharmacy
  • Hospital Pharmacy
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Anti-hypertensive Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Anti-hypertensive Drugs Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. ACE Inhibitors (ACEIs)
    • 4.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Angiotensin II Receptor Blockers (ARBs)
    • 4.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Direct Renin Inhibitor
    • 4.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Calcium Channel Blockers
    • 4.7.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Diuretics
    • 4.8.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.9. Mineralocorticoid Receptor Antagonists (MRAs)
    • 4.9.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.10. Beta-Blockers
    • 4.10.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.11. Alpha-1 Blockers
    • 4.11.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.12. Central Alpha-2 Agonists
    • 4.12.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.13. Direct Vasodilators
    • 4.13.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.14. Fixed-Dose Combinations (FDCs)
    • 4.14.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.15. Others
    • 4.15.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Anti-hypertensive Drugs Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2033
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Standard Hypertension
    • 5.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Treatment-Resistant Hypertension
    • 5.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Hypertensive Emergency/Urgency
    • 5.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Anti-hypertensive Drugs Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Oral
    • 6.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Transdermal
    • 6.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Parenteral / Intravenous
    • 6.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Anti-hypertensive Drugs Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 7.4. Retail Pharmacy
    • 7.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Hospital Pharmacy
    • 7.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Other
    • 7.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Anti-hypertensive Drugs Market: Countries Estimates & Trend Analysis

  • 8.1. Country Market Share Analysis, 2024 & 2033
  • 8.2. Country Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Anti-Hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Sanofi
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Bayer
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Boehringer Ingelheim International GmbH
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. DAIICHI SANKYO COMPANY, LIMITED
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Takeda Pharmaceutical Company Limited
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Viatris Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Teva Pharmaceutical Industries Ltd.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Sandoz (Novartis)
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Sun Pharmaceutical Industries Ltd.
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Anti-Hypertensive Drugs Market, By Region, 2021 - 2033 (USD Million)
  • Table 3 Global Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 4 Global Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 5 Global Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 6 Global Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 7 North America Anti-Hypertensive Drugs Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 9 North America Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 10 North America Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 11 North America Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 12 U.S Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 13 U.S Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 14 U.S Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 15 U.S Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 16 Canada Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 17 Canada Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 18 Canada Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 19 Canada Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 20 Mexico Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 21 Mexico Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 23 Mexico Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 24 Europe Anti-Hypertensive Drugs Market, By Country, 2021 - 2033 (USD Million)
  • Table 25 Europe Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 26 Europe Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 27 Europe Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 28 Europe Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 29 Germany Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 30 Germany Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 31 Germany Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 32 Germany Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 33 UK Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 34 UK Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 35 UK Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 36 UK Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 37 France Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 38 France Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 39 France Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 40 France Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 41 Italy Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 42 Italy Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 44 Italy Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 45 Spain Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 46 Spain Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 47 Spain Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 48 Spain Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 49 Denmark Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 50 Denmark Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 51 Denmark Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 52 Denmark Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 53 Sweden Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 54 Sweden Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 55 Sweden Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 56 Sweden Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 57 Norway Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 58 Norway Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 59 Norway Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 60 Norway Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific Anti-Hypertensive Drugs Market, By Country, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 66 China Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 67 China Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 68 China Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 69 China Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 70 Japan Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 71 Japan Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 72 Japan Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 73 Japan Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 74 India Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 75 India Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 76 India Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 77 India Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 78 South Korea Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 79 South Korea Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 80 South Korea Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 81 South Korea Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 82 Australia Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 83 Australia Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 84 Australia Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 85 Australia Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 86 Thailand Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 87 Thailand Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 88 Thailand Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 89 Thailand Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 90 Latin America Anti-Hypertensive Drugs Market, By Country, 2021 - 2033 (USD Million)
  • Table 91 Latin America Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 92 Latin America Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 94 Latin America Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 95 Brazil Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 96 Brazil Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 98 Brazil Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 99 Argentina Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 100 Argentina Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 102 Argentina Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 103 Middle East & Africa Anti-Hypertensive Drugs Market, By Country, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 108 South Africa Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 109 South Africa Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 111 South Africa Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 116 UAE Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 117 UAE Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 118 UAE Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 119 UAE Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 120 Kuwait Anti-Hypertensive Drugs Market, By Product, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Anti-Hypertensive Drugs Market, By Type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Anti-Hypertensive Drugs Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Anti-Hypertensive Drugs Market, By Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Anti-Hypertensive Drugs Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product Segment snapshot
  • Fig. 10 Type and Route of Administration Segment Snapshot
  • Fig. 11 Distribution channel segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Parent market (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE Analysis
  • Fig. 17 Anti-Hypertensive Drugs market: Indication outlook and key takeaways
  • Fig. 18 Anti-Hypertensive drugs market: product movement analysis
  • Fig. 19 ACE Inhibitors (ACEIs) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Angiotensin II Receptor Blockers (ARBs) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Direct Renin Inhibitor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Calcium Channel Blockers (CCBs) [Dihydropyridines, Non Dihydropyridines] market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Diuretics (non-MRA) [Thiazide & Thiazide-like, Loop Diuretics, Potassium-Sparing (non-MRA)] market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Mineralocorticoid Receptor Antagonists (MRAs) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Beta-Blockers [Cardioselective, Non-selective / Mixed] market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Alpha-1 Blockers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Central Alpha-2 Agonists market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Direct Vasodilators market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Fixed-Dose Combinations (FDCs) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Other market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Anti-Hypertensive Drugs market: Type outlook and key takeaways
  • Fig. 32 Anti-Hypertensive Drugs market: Type movement analysis
  • Fig. 33 Standard Hypertension (patients controlled with <=3 agents) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Treatment-Resistant Hypertension (TRH) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Hypertensive Emergency/Urgency (IV/acute use) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Anti-Hypertensive drugs market: Route of administration outlook and key takeaways
  • Fig. 37 Anti-Hypertensive drugs market: Route of administration movement analysis
  • Fig. 38 Oral (tablets, capsules) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Transdermal (patches) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Parenteral / Intravenous market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Anti-Hypertensive drugs market: Distribution channel outlook and key takeaways
  • Fig. 42 Anti-Hypertensive drugs market: Distribution channel movement analysis
  • Fig. 43 Hospital pharmacy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Retail pharmacy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Anti-Hypertensive Drugs market revenue, by region, 2021 & 2033, USD Million
  • Fig. 47 Regional marketplace: Key takeaways
  • Fig. 48 Regional marketplace: Key takeaways
  • Fig. 49 North America Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 50 Key country dynamics
  • Fig. 51 U S Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 52 General reimbursement pattern in the U S
  • Fig. 53 Key country dynamics
  • Fig. 54 Canada Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 55 Key country dynamics
  • Fig. 56 Mexico Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 57 Regulatory framework
  • Fig. 58 Europe Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 59 Key country dynamics
  • Fig. 60 UK Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 61 Key country dynamics
  • Fig. 62 Germany Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 63 Key country dynamics
  • Fig. 64 France Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 65 Key country dynamics
  • Fig. 66 Spain Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 67 Key country dynamics
  • Fig. 68 Italy Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 69 Key country dynamics
  • Fig. 70 Denmark Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 71 Key country dynamics
  • Fig. 72 Sweden Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 73 Key country dynamics
  • Fig. 74 Norway Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 75 Asia Pacific Anti-Hypertensive drugs market estimates and forecast, 2021 - 2033, USD Million
  • Fig. 76 Key country dynamics
  • Fig. 77 Japan Anti-Hypertensive drugs market estimates and forecast, 2021 - 2033, USD Million
  • Fig. 78 Key country dynamics
  • Fig. 79 China Anti-Hypertensive drugs market estimates and forecast, 2021 - 2033 USD Million
  • Fig. 80 China regulatory details
  • Fig. 81 Key country dynamics
  • Fig. 82 India Anti-Hypertensive drugs market estimates and forecast, 2021 - 2033, USD Million
  • Fig. 83 Key country dynamics
  • Fig. 84 Australia Anti-Hypertensive drugs market estimates and forecast, 2021 - 2033, USD Million
  • Fig. 85 Key country dynamics
  • Fig. 86 Thailand Anti-Hypertensive drugs market estimates and forecast, 2021 - 2033, USD Million
  • Fig. 87 Key country dynamics
  • Fig. 88 South Korea Anti-Hypertensive drugs market estimates and forecast, 2021 - 2033, USD Million
  • Fig. 89 South Korea reimbursement scenario
  • Fig. 90 Latin America Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 91 Key country dynamics
  • Fig. 92 Brazil Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 93 Brazil regulation details
  • Fig. 94 Brazil reimbursement scenario
  • Fig. 95 Key country dynamics
  • Fig. 96 Argentina Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 97 Argentina regulatory framework
  • Fig. 98 MEA Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 99 Key country dynamics
  • Fig. 100 South Africa Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Saudi Arabia Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 103 Key country dynamics
  • Fig. 104 UAE Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million
  • Fig. 105 Key country dynamics
  • Fig. 106 Kuwait Anti-Hypertensive drugs market estimates and forecasts, 2021 - 2033 USD Million